Biotechnology
Compare Stocks
5 / 10Stock Comparison
OKYO vs SGHT vs LNTH vs NVCR vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Drug Manufacturers - Specialty & Generic
Medical - Instruments & Supplies
Medical - Devices
OKYO vs SGHT vs LNTH vs NVCR vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Devices | Drug Manufacturers - Specialty & Generic | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $66M | $293M | $6.06B | $2.04B | $97.62B |
| Revenue (TTM) | $0.00 | $80M | $1.55B | $674M | $35.48B |
| Net Income (TTM) | $-5M | $-37M | $279M | $-173M | $4.61B |
| Gross Margin | — | 86.2% | 60.5% | 75.2% | 61.9% |
| Operating Margin | — | -44.8% | 18.8% | -27.2% | 17.9% |
| Forward P/E | — | — | 17.7x | — | 13.8x |
| Total Debt | $0.00 | $41M | $738K | $290M | $28.52B |
| Cash & Equiv. | $2M | $92M | $359M | $103M | $2.22B |
OKYO vs SGHT vs LNTH vs NVCR vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| OKYO Pharma Limited (OKYO) | 100 | 79.5 | -20.5% |
| Sight Sciences, Inc. (SGHT) | 100 | 62.6 | -37.4% |
| Lantheus Holdings, … (LNTH) | 100 | 135.8 | +35.8% |
| NovoCure Limited (NVCR) | 100 | 22.3 | -77.7% |
| Medtronic plc (MDT) | 100 | 76.0 | -24.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKYO vs SGHT vs LNTH vs NVCR vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, OKYO doesn't own a clear edge in any measured category.
SGHT is the #2 pick in this set and the best alternative if momentum is your priority.
- +77.6% vs MDT's -5.5%
LNTH ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.
- 42.9% 10Y total return vs MDT's 24.3%
- Lower volatility, beta 0.45, Low D/E 0.1%, current ratio 2.70x
- 18.0% margin vs SGHT's -46.8%
NVCR is the clearest fit if your priority is growth exposure.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 8.3% revenue growth vs OKYO's -11K%
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.42, yield 3.7%
- Beta 0.42, yield 3.7%, current ratio 1.85x
- Better valuation composite
- Beta 0.42 vs SGHT's 2.41, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.3% revenue growth vs OKYO's -11K% | |
| Value | Better valuation composite | |
| Quality / Margins | 18.0% margin vs SGHT's -46.8% | |
| Stability / Safety | Beta 0.42 vs SGHT's 2.41, lower leverage | |
| Dividends | 3.7% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +77.6% vs MDT's -5.5% | |
| Efficiency (ROA) | 175.8% ROA vs OKYO's -128.4% |
OKYO vs SGHT vs LNTH vs NVCR vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
OKYO vs SGHT vs LNTH vs NVCR vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LNTH leads in 3 of 6 categories
MDT leads 2 • OKYO leads 0 • SGHT leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
LNTH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT and OKYO operate at a comparable scale, with $35.5B and $0 in trailing revenue. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to SGHT's -46.8%. On growth, SGHT holds the edge at +12.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $80M | $1.5B | $674M | $35.5B |
| EBITDAEarnings before interest/tax | -$4M | -$35M | $347M | -$165M | $9.4B |
| Net IncomeAfter-tax profit | -$5M | -$37M | $279M | -$173M | $4.6B |
| Free Cash FlowCash after capex | -$2M | -$25M | $372M | -$48M | $5.4B |
| Gross MarginGross profit ÷ Revenue | — | +86.2% | +60.5% | +75.2% | +61.9% |
| Operating MarginEBIT ÷ Revenue | — | -44.8% | +18.8% | -27.2% | +17.9% |
| Net MarginNet income ÷ Revenue | — | -46.8% | +18.0% | -25.7% | +13.0% |
| FCF MarginFCF ÷ Revenue | — | -31.9% | +24.0% | -7.1% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.5% | +1.2% | +12.3% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.3% | +14.3% | +76.5% | -100.0% | -11.9% |
Valuation Metrics
MDT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 21.1x trailing earnings, MDT trades at a 23% valuation discount to LNTH's 27.3x P/E. On an enterprise value basis, MDT's 14.1x EV/EBITDA is more attractive than LNTH's 15.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $66M | $293M | $6.1B | $2.0B | $97.6B |
| Enterprise ValueMkt cap + debt − cash | $65M | $242M | $5.7B | $2.2B | $123.9B |
| Trailing P/EPrice ÷ TTM EPS | -13.58x | -7.27x | 27.29x | -14.66x | 21.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 17.70x | — | 13.80x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 35.17x |
| EV / EBITDAEnterprise value multiple | — | — | 14.96x | — | 14.06x |
| Price / SalesMarket cap ÷ Revenue | — | 3.78x | 3.93x | 3.11x | 2.91x |
| Price / BookPrice ÷ Book value/share | — | 4.39x | 5.84x | 5.86x | 2.04x |
| Price / FCFMarket cap ÷ FCF | — | — | 17.11x | — | 18.83x |
Profitability & Efficiency
LNTH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-59 for SGHT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs OKYO's 3/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -59.1% | +24.3% | -50.8% | +9.4% |
| ROA (TTM)Return on assets | -128.4% | -32.2% | +12.4% | -16.5% | +175.8% |
| ROICReturn on invested capital | — | -2.7% | +30.6% | -16.4% | +6.0% |
| ROCEReturn on capital employed | — | -32.0% | +17.1% | -28.9% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 5 | 5 | 6 |
| Debt / EquityFinancial leverage | — | 0.64x | 0.00x | 0.85x | 0.59x |
| Net DebtTotal debt minus cash | -$2M | -$51M | -$358M | $187M | $26.3B |
| Cash & Equiv.Liquid assets | $2M | $92M | $359M | $103M | $2.2B |
| Total DebtShort + long-term debt | $0 | $41M | $738,000 | $290M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -8.03x | -14.04x | 15.83x | -96.80x | 9.08x |
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $43,814 today (with dividends reinvested), compared to $983 for NVCR. Over the past 12 months, SGHT leads with a +77.6% total return vs MDT's -5.5%. The 3-year compound annual growth rate (CAGR) favors LNTH at -0.6% vs NVCR's -36.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -26.9% | -28.1% | +38.3% | +36.4% | -20.0% |
| 1-Year ReturnPast 12 months | +10.1% | +77.6% | +15.7% | +2.6% | -5.5% |
| 3-Year ReturnCumulative with dividends | -23.5% | -48.9% | -1.9% | -74.2% | -6.3% |
| 5-Year ReturnCumulative with dividends | -55.0% | -83.9% | +338.1% | -90.2% | -29.2% |
| 10-Year ReturnCumulative with dividends | -55.0% | -83.9% | +4289.6% | +38.5% | +24.3% |
| CAGR (3Y)Annualised 3-year return | -8.5% | -20.0% | -0.6% | -36.4% | -2.1% |
Risk & Volatility
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than SGHT's 2.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 98.1% from its 52-week high vs OKYO's 48.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 2.41x | 0.45x | 2.15x | 0.42x |
| 52-Week HighHighest price in past year | $3.35 | $9.24 | $94.86 | $20.06 | $106.33 |
| 52-Week LowLowest price in past year | $1.32 | $2.81 | $47.25 | $9.82 | $75.91 |
| % of 52W HighCurrent price vs 52-week peak | +48.7% | +58.3% | +98.1% | +89.2% | +71.6% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 70.2 | 69.9 | 70.9 | 29.2 |
| Avg Volume (50D)Average daily shares traded | 93K | 359K | 872K | 1.4M | 7.9M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: SGHT as "Buy", LNTH as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 6.7% for LNTH (target: $99). MDT is the only dividend payer here at 3.65% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $9.67 | $99.25 | $33.50 | $109.50 |
| # AnalystsCovering analysts | — | 9 | 17 | 15 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.7% |
| Dividend StreakConsecutive years of raises | 1 | — | 0 | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +5.0% | 0.0% | +3.3% |
LNTH leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
OKYO vs SGHT vs LNTH vs NVCR vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OKYO or SGHT or LNTH or NVCR or MDT a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus -3. 1% for Sight Sciences, Inc. (SGHT). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Sight Sciences, Inc. (SGHT) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OKYO or SGHT or LNTH or NVCR or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
1x versus Lantheus Holdings, Inc. at 27. 3x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x.
03Which is the better long-term investment — OKYO or SGHT or LNTH or NVCR or MDT?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +338. 1%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus SGHT's -83. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OKYO or SGHT or LNTH or NVCR or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
42β versus Sight Sciences, Inc. 's 2. 41β — meaning SGHT is approximately 467% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — OKYO or SGHT or LNTH or NVCR or MDT?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus -3. 1% for Sight Sciences, Inc. (SGHT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OKYO or SGHT or LNTH or NVCR or MDT?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus -49. 7% for Sight Sciences, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -48. 0% for SGHT. At the gross margin level — before operating expenses — SGHT leads at 86. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OKYO or SGHT or LNTH or NVCR or MDT more undervalued right now?
On forward earnings alone, Medtronic plc (MDT) trades at 13.
8x forward P/E versus 17. 7x for Lantheus Holdings, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 87. 3% to $33. 50.
08Which pays a better dividend — OKYO or SGHT or LNTH or NVCR or MDT?
In this comparison, MDT (3.
7% yield) pays a dividend. OKYO, SGHT, LNTH, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is OKYO or SGHT or LNTH or NVCR or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
42), 3. 7% yield). Sight Sciences, Inc. (SGHT) carries a higher beta of 2. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, SGHT: -83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OKYO and SGHT and LNTH and NVCR and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OKYO is a small-cap quality compounder stock; SGHT is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while OKYO, SGHT, LNTH, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.